Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first Hanf.com in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks Hanf.com's fifth franchise agreement and the second store in the state of North Rhine-Westphalia.
Hanf.com is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin.
As part of the event's vibrant exhibition floor, Hanf.com will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find Hanf.com at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space.
Alex Cerveny, COO of Hanf.com commented: "We are excited to bring the Hanf.com experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the Hanf.com brand."
"We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations."
Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day.
About Neural Therapeutics
Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy.
On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand Hanf.com, to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation.
For further inquiries, please contact:
Neural Therapeutics Inc.
Ian Campbell, CEO
E: icampbell@neuraltherapeutics.ca
T: +1 (647) 697-NURL (6875)
Marc Lakmaaker
E: mlakmaaker@gmail.com
T: +1.647.289.6640
CAUTIONARY DISCLAIMER STATEMENT
No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as Hanf.com), the timing and scope of Hanf.com's participation at Mary Jane Berlin 2025, the growth and performance of Hanf.com's business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of Hanf.com's products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on www.sedarplus.ca.
The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254676
Hanf.com is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin.
As part of the event's vibrant exhibition floor, Hanf.com will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find Hanf.com at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space.
Alex Cerveny, COO of Hanf.com commented: "We are excited to bring the Hanf.com experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the Hanf.com brand."
"We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team." Mr. Cerveny added: "This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations."
Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day.
About Neural Therapeutics
Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy.
On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand Hanf.com, to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation.
For further inquiries, please contact:
Neural Therapeutics Inc.
Ian Campbell, CEO
E: icampbell@neuraltherapeutics.ca
T: +1 (647) 697-NURL (6875)
Marc Lakmaaker
E: mlakmaaker@gmail.com
T: +1.647.289.6640
CAUTIONARY DISCLAIMER STATEMENT
No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating opening of new franchise locations by CWE (operating as Hanf.com), the timing and scope of Hanf.com's participation at Mary Jane Berlin 2025, the growth and performance of Hanf.com's business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of Hanf.com's products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on www.sedarplus.ca.
The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254676
